High-content assay to identify inhibitors of dengue virus infection

Assay and Drug Development Technologies

Volumn 8, Issue 5, 2010, Pages 553-570

  Shum, David ^a   Smith, Jessica L ^b   Hirsch, Alec J ^b   Bhinder, Bhavneet ^a   Radu, Constantin ^a   Stein, David A ^b   Nelson, Jay A ^b   Früh, Klaus ^b   Djaballah, Hakim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 3ALPHA [(4 CHLOROPHENYL)PHENYLMETHOXY]TROPANE; 4 (7,8,9,10 TETRAHYDRO 5,7,7,10,10 PENTAMETHYL 5H BENZO[E]NAPHTHO[2,3 B][1,4]DIAZEPIN 13 YL)BENZOIC ACID; ACETYLSPIRAMYCIN; ACRIFLAVINE; ANTIVIRUS AGENT; AZ 10417808; BEBEERINE; BENZETHONIUM CHLORIDE; BIBU 1361; CARRAGEENAN; COLISTIN; CYTOCHALASIN A; CYTOCHALASIN B; DASATINIB; DAUNORUBICIN; MEPACRINE; MERBROMIN; N (6 AMINOHEXYL) 5 CHLORO 2 NAPHTHALENESULFONAMIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NIGULDIPINE; NSC 95397; POLYSACCHARIDE; PROTEIN KINASE; RECEPTOR; RIBAVIRIN; SELAMECTIN; TANNIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; ASSAY; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOTOXICITY; DENGUE; DENGUE VIRUS; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG SCREENING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; MOSQUITO; NONHUMAN; SIGNAL TRANSDUCTION; STAINING; VALIDATION PROCESS; VIRUS CELL INTERACTION; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; CELL SURVIVAL; DENGUE; DENGUE VIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, CONFOCAL; MINIATURIZATION; SOFTWARE; VIRAL PROTEINS; VIRUS ATTACHMENT;

EID: 77958613347     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2010.0321     Document Type: Article

References (36)

1. Chambers TJ, Hahn CS, Galler R, Rice CM: Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990;44:649-688.
2. Lindenbach BD, Rice CM: Molecular biology of flaviviruses. Adv Virus Res 2003;59:23-61.
3. Gubler DJ, Meltzer M: Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Res 1999;53:35-70.
4. Gubler DJ: Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998;11:480-496.
5. Takhampunya R, Ubol S, Houng HS, et al.: Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J Gen Virol 2006;87:1947-1952.
6. Diamond MS, Zachariah M, Harris E: Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 2002;304:211-221.
7. Wu SF, Lee CJ, Liao CL, et al.: Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol 2002;76:3596-3604.
8. Olsen DB, Eldrup AB, Bartholomew L, et al.: A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 2004;48:3944-3953.
9. Whitby K, Pierson TC, Geiss B, et al.: Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol 2005;79:8698-8706.
10. Zhang XG, Mason PW, Dubovi EJ, et al.: Antiviral activity of geneticin against dengue virus. Antiviral Res 2009;83:21-27.
11. Yin Z, Chen YL, Schul W, et al.: An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci USA 2009;106:20435-20439.
12. Rodenhuis-Zybert IA, Wilschut J, Smit JM: Dengue virus life cycle: viral and host factors modulating infectivity. Cell Mol Life Sci 2010;67:2773-2786.
13. Martina BE, Koraka P, Osterhaus AD: Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 2009;22:564-581.
14. Pastorino B, Nougairède A, Wurtz N, et al.: Role of host cell factors in flavivirus infection: implications for pathogenesis and development of antiviral drugs. Antiviral Res 2010;87:281-294.
15. Morrey JD, Smee DF, Sidwell RW, Tseng C: Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res 2002;55:107-116.
16. Tomlinson SM, Malmstrom RD, Russo A,Mueller N,et al.: Structure based discovery of dengue virus protease inhibitors. Antiviral Res 2009;82:110-114.
17. Che P, Wang L, Li Q: The development, optimization and validation of an assay for high throughput antiviral drug screening against Dengue virus. Int J Clin Exp Med 2009;2:363-373.
18. Qing M, Liu W, Yuan Z, et al.: A high-throughput assay using dengue-1 viruslike particles for drug discovery. Antiviral Res 2010;86:163-171.
19. Chu JJ, Yang PL: c-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proc Natl Acad Sci USA 2007;104:3520-3525.
20. Antczak C, Takagi T, Ramirez CN, et al.: Live-cell imaging of caspase activation for high-content screening. J Biomol Screen 2009;14:956-969.
21. Ivnitski-Steele I, Ramirez CN, Djaballah H: Human embryonic stem cells in drug discovery: are we there yet? Int Drug Discov 2010;5:24-28.
22. Desbordes SC, Placantonakis DG, Ciro A, et al.: High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell 2008;2:602-612.
23. Henchal EA, Gentry MK, McCown JM, Brandt WE: Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 1982;31:830-836.
24. Shelton CC, Tian Y, Shum D, et al.: A miniaturized 1536-well format gamma-secretase assay. Assay Drug Dev Technol 2009;7:461-470.
25. Zhang JH, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
26. Talavera D, Castillo AM, Dominguez MC, et al.: IL8 release, tight junction and cytoskeleton dynamic reorganization conducive to permeability increase are induced by dengue virus infection of microvascular endothelial monolayers. J Gen Virol 2004;85:1801-1813.
27. Leyssen P, Balzarini J, De Clercq E, Neyts J: The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 2005;79:1943-1947.
28. Trujillo-Murillo K, Rincón-Sánchez AR, Martínez- Rodríguez H, et al.: Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology 2008;47:1462-1472.
29. Talarico LB, Damonte EB: Interference in dengue virus adsorption and uncoating by carrageenans. Virology 2007;363:473-485.
30. Deng L, Dai P, Ciro A, et al.: Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol 2007;81:13392-13402.
31. Noble CG, Chen YL, Dong H, et al.: Strategies for development of dengue virus inhibitors. Antiviral Res 2010;85:450-462.
32. Mueller NH, Pattabiraman N, Ansarah-Sobrinho C, et al.: Identification and biochemical characterization of small-molecule inhibitors of West Nile virus serine protease by a high-throughput screen. Antimicrob Agents Chemother 2008;52:3385-3393.
33. Wang QY, Patel SJ, Vangrevelinghe E, et al.: A small-molecule dengue virus entry inhibitor. Antimicrob Agents Chemother 2009;53:1823-1831.
34. Niyomrattanakit P, Chen YL, Dong H, et al.: Inhibition of dengue virus polymerase by blocking of the RNA tunnel. J Virol 2010;84:5678-5686.
35. Bodenreider C, Beer D, Keller TH, et al.: A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal Biochem 2009;395:195-204.
36. Massé N, Davidson A, Ferron F, et al.: Dengue virus replicons: production of an interserotypic chimera and cell lines from different species, and establishment of a cell-based fluorescent assay to screen inhibitors, validated by the evaluation of ribavirin's activity. Antiviral Res 2010;86:296-305.